



Take the Next Step

If you are 18 years or older and have hidradenitis suppurativa (HS), you may qualify for a local clinical research study. The study is for an investigational medication for HS, taken once daily by mouth.

Selected Eligibility Criteria

- ✓ Have had hidradenitis suppurativa (HS) for at least 3 months
- ✓ Have been prescribed an HS treatment that did not improve your symptoms
- ✓ Have at least 5 active HS lesions (such as bumps, boils and/or abscesses)
- ✓ Are able to attend regular visits at your study doctor's office over an approximate 13-month period

To learn more, and to see if you might qualify, please contact us
Site Details:




Researching a potential
new option for

Hidradenitis Suppurativa (HS)


CLINICAL RESEARCH
STUDY INFORMATION

Are you living with hidradenitis suppurativa (HS)?

Hidradenitis suppurativa (HS), or acne inversa, is a skin condition that causes painful bumps, boils and/or abscesses to form under the skin. HS usually appears in areas where skin rubs together, such as the armpits, groin, inner thighs, buttocks and breasts. As HS gets more severe, these bumps, boils and/or abscesses can rupture or leak and cause scarring. HS develops after puberty or in early adulthood, but often takes years to diagnose - and like many skin conditions can take a major toll on self-esteem and quality of life. Currently, there is no cure for HS, but researchers are studying new options that may be able to help.



*HS can affect one spot or multiple areas of the body
- often where skin rubs together and where sweat
glands and hair follicles are located.*



You may be interested in a new clinical research study.

Right now, doctors at select centers worldwide are accepting participants for a new clinical research study. The study is for an investigational oral medication for hidradenitis suppurativa (HS), taken once daily. **If you have had hidradenitis suppurativa (HS) for at least 3 months, and have been prescribed in the past with an HS treatment that did not work well**, you may qualify to participate.

Participants in the study will receive study-related care and medication at no cost. For the first 3 months of the study, participants will be randomly assigned to take either the active investigational medication (67% chance) or a placebo (33% chance). The placebo is an identical-looking medication, but with no active ingredient. Neither you nor your study doctor will know which medication you are receiving during this time. This is a common technique in clinical studies, as it helps doctors and researchers understand the effects of the investigational medication without bias.

However, after this 3-month period, participants will receive only the active investigational medication at no cost for an additional 10 months - there is no placebo during this period. Throughout the study, you will meet with your study doctor at regular intervals to track your progress and discuss your overall experiences. You will be compensated for your time and travel to attend these visits.

To learn more, please contact us

STOP-HS2 Trial
Department of Dermatology, Princess Alexandra Hospital, Brisbane, Australia
Email: HS-Derm@health.qld.gov.au